MOHAP (Uae)

MoHAP (the Ministry of Health and Prevention) is the United Arab Emirates federal regulatory authority responsible for the regulation of human medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + dietary supplements + pharmacy practice + controlled substances across the seven Emirates (Abu Dhabi, Dubai, Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah, Fujairah). MoHAP operates under Federal Law 4 of 1983 (Pharmacy Profession + Pharmaceutical Establishments — historic framework) + Federal Law 8 of 2019 (Medical Products + Pharmacy Profession + Pharmaceutical Establishments — modernised framework substantially replacing 1983 Law) + Federal Cabinet Decisions + Ministerial Decisions + MoHAP Decisions + Guidance Documents.

The UAE pharmaceutical regulatory landscape is distinctively federally-coordinated with substantial Emirate-level delegation. Three regulators operate concurrently with defined jurisdictional + coordinated functions:

• MoHAP (Ministry of Health and Prevention, federal) — federal drug + biological + vaccine + medical-device + cosmetic + dietary-supplement registration; federal GMP/GDP/GPP inspection; federal pharmacovigilance + matériovigilance coordination; federal controlled-substances + anti-counterfeit coordination; coordination with all seven Emirates including direct healthcare-facility + pharmacy regulation in Sharjah + Ajman + Umm Al Quwain + Ras Al Khaimah + Fujairah (the five Northern Emirates).
• DHA (Dubai Health Authority, Emirate-level) — Dubai-specific pharmacy + healthcare-facility + pharmaceutical-establishment licensing + selected product registration + Dubai Drug List; coordinates with MoHAP on federal Drug Registration; operates Dubai Healthcare City (DHCC) Authority for free-zone healthcare + pharmaceutical regulatory coordination.
• DoH Abu Dhabi (Department of Health Abu Dhabi, Emirate-level) — Abu Dhabi-specific pharmacy + healthcare-facility + pharmaceutical-establishment licensing + selected product registration + Abu Dhabi Drug List + Abu Dhabi Stem Cell Center oversight + advanced therapy medicinal products (ATMP) coordination; coordinates with MoHAP on federal Drug Registration; operates Abu Dhabi Global Market (ADGM) free-zone healthcare + pharmaceutical regulatory coordination.

MoHAP's organisational structure includes:

• Minister of Health and Prevention — political head appointed by Federal Cabinet.
• Undersecretary — administrative head responsible for day-to-day MoHAP operations.
• Drug Registration Department — drug + biological + vaccine + biosimilar + generic-medicine federal registration via Drug Registration procedure.
• Medical Devices Department — medical-device + IVD federal registration + post-market matériovigilance.
• Pharmaceutical Inspection Department — UAE + foreign manufacturer + distributor + pharmacy GMP/GDP/GPP/GVP/GLP inspections.
• Pharmacovigilance Department — UAE Federal Pharmacovigilance Programme + WHO PIDM coordination.
• Pharmacy Practice + Pharmaceutical Establishments Department — federal pharmacy practice + pharmaceutical-establishment licensing in the five Northern Emirates (Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah, Fujairah).
• Cosmetics + Dietary Supplements Department — cosmetic-product + dietary-supplement notification + post-market vigilance.
• Controlled Substances Department — federal controlled-substances + narcotics + psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988; coordinates with INCB + UAE Ministry of Interior + Federal Customs Authority.
• International Affairs Department — international cooperation + WHO + EMA + FDA + Health Canada + GHC + Arab League + ICH + IMDRF coordination.
• MoHAP Central Laboratories (Dubai) — central pharmaceutical + medical-device QC laboratory; ISO/IEC 17025 accredited.
• UAE Federal Pharmacovigilance Centre (Dubai) — federal integrated pharmacovigilance + matériovigilance + cosmétovigilance centre operating under MoHAP coordination.
• Federal Anti-Counterfeit Coordination — coordination with UAE Federal Customs Authority + Ministry of Interior + Dubai Police + Abu Dhabi Police for counterfeit-medicine enforcement.

MoHAP is distinct from + complementary to: the federal Ministry of Industry and Advanced Technology (industrial-policy + Emirati pharmaceutical manufacturing strategy via Operation 300bn + Make it in the Emirates); the federal Emirates Authority for Standardization and Metrology (ESMA — standards + accreditation including pharmaceutical + medical-device); the federal Insurance Authority (health-insurance coordination); the Emirates Drug Establishment (EDE — federal pharmaceutical-procurement coordination); the Pharmaceutical Society of the UAE (PSUAE, pharmacist professional body); + Emirate-level Emirate-Owned Pharmaceutical Distribution Companies. The UAE pharmaceutical environment is characterised by: substantial pharmaceutical import + re-export hub function (Jebel Ali Free Zone + Dubai Healthcare City + Abu Dhabi Global Market hosting substantial pharmaceutical logistics + regulatory + manufacturing infrastructure); growing domestic pharmaceutical manufacturing (Julphar — Gulf Pharmaceutical Industries based in Ras Al Khaimah, Globalpharma in Dubai, Neopharma in Abu Dhabi, Pharmax in Dubai, Medpharma in Sharjah, Abu Dhabi-based G42 Healthcare biotechnology); + strategic GCC + MENA + sub-Saharan Africa + South Asia + Central Asia + global re-export positioning.

Legal foundations are Federal Law 4 of 1983 (historic Pharmacy Profession + Pharmaceutical Establishments framework); Federal Law 8 of 2019 (modernised Medical Products + Pharmacy Profession + Pharmaceutical Establishments framework substantially replacing 1983 Law); Federal Decree-Law 8 of 2019 (Medical Liability); Federal Law 28 of 2005 (Controlled Substances + Narcotics + Psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988); Federal Decisions on Medical Devices + Cosmetics + Dietary Supplements; DHA Health Regulation Department Decisions; DoH Abu Dhabi Health Regulation Sector Decisions; + a substantial body of MoHAP + DHA + DoH Abu Dhabi Decisions + Guidance Documents. UAE pharmaceutical regulation operates substantively in Arabic (official Constitutional language) with English (working language + scientific publication + commercial language) labelling requirements.

MoHAP is a Gulf Health Council (GHC) Member State authority + an active GCC Drug Registration co-leader (alongside SFDA + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH) + a League of Arab States Council of Arab Ministers of Health pharmaceutical-harmonisation co-leader + an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority + a PIC/S Pre-Accession Applicant + an ICH Observer + an IMDRF Affiliate + holds Working Arrangements with EMA + FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS.

UAE pharmaceutical regulation operates under a layered framework of Federal Laws + Federal Cabinet Decisions + Ministerial Decisions + MoHAP + DHA + DoH Abu Dhabi Decisions + Guidance Documents:

• Federal Law 4 of 1983 — historic Pharmacy Profession + Pharmaceutical Establishments framework.
• Federal Law 8 of 2019 — modernised Medical Products + Pharmacy Profession + Pharmaceutical Establishments framework substantially replacing 1983 Law.
• Federal Law 28 of 2005 — Controlled Substances + Narcotics + Psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988.
• Federal Decree-Law 8 of 2019 — Medical Liability framework.
• Federal Cabinet Decisions on Medical Devices + Cosmetics + Dietary Supplements.
• MoHAP GMP Guide — substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2 + GCC GMP.
• MoHAP GDP Guide — substantively aligned with WHO + EU GDP + GCC GDP.
• MoHAP GCP Guide — substantively aligned with ICH E6(R2) + GCC GCP.
• MoHAP GVP Guide — substantively aligned with ICH E2 + EU GVP + GCC GVP.
• GCC Pharmacopoeia + recognises British Pharmacopoeia + USP + European Pharmacopoeia + Arab Pharmacopoeia.
• GCC Drug Registration framework — substantively harmonised registration procedure across GCC Member States.
• MoHAP Medical Devices framework — Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF + GCC-MD.
• MoHAP Cosmetics framework — substantively aligned with EU Cosmetics Regulation including INCI ingredient listing + safety substantiation + cosmétovigilance.
• MoHAP Variations + 5-year Drug Registration Renewal framework.
• DHA Health Regulation Department Decisions — Dubai-specific pharmacy + healthcare-facility + pharmaceutical-establishment licensing + Dubai Drug List.
• DoH Abu Dhabi Health Regulation Sector Decisions — Abu Dhabi-specific pharmacy + healthcare-facility + pharmaceutical-establishment licensing + Abu Dhabi Drug List + advanced therapy medicinal products coordination.

MoHAP Central Laboratories is MoHAP's central pharmaceutical + medical-device quality-control laboratory in Dubai + is ISO/IEC 17025 accredited (EIAC — Emirates International Accreditation Centre). MoHAP Central Laboratories is pursuing WHO PQ-Lab designation, which would position it alongside Egypt EDA NODCAR + Morocco LNCM + Tunisia LNCM + Jordan JFDA Central Laboratories + Saudi SFDA Central Laboratory as the WHO-prequalified pharmaceutical QC laboratory complex in the MENA region. UAE additionally benefits from GCC Pharmaceutical Inspection cooperation — harmonised GCC-Member-State pharmaceutical inspection providing efficient cross-Member-State inspection coordination + reliance + recognition.

• ISO/IEC 17025 Accreditation — MoHAP Central Laboratories is ISO/IEC 17025 accredited (EIAC — Emirates International Accreditation Centre) across multiple testing scopes including pharmaceutical chemical + microbiological + biological + medical-device testing.
• WHO PQ-Lab Candidate — MoHAP Central Laboratories is pursuing WHO PQ-Lab designation; would provide UAE with WHO-recognised pharmaceutical QC capacity.
• GCC Pharmaceutical Inspection — UAE participates in GCC harmonised pharmaceutical inspection providing efficient cross-Member-State inspection coordination + reliance + recognition with Saudi SFDA + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH.
• GCC Centralized Drug Registration — substantively harmonised registration procedure across GCC Member States; approved-in-one-GCC-Member-State products eligible for accelerated review in other Member States.
• Vaccine lot release — MoHAP Central Laboratories conducts vaccine lot-release testing for MoHAP + UAE National Immunization Programme.
• Pharmaceutical pre-registration + post-market testing — MoHAP Central Laboratories conducts pre-registration quality testing + post-market surveillance + targeted enforcement testing for MoHAP.
• Medical-device + IVD testing — MoHAP Central Laboratories conducts medical-device + IVD pre-market + post-market quality testing.
• Cosmetic-product + dietary-supplement testing — MoHAP Central Laboratories conducts cosmetic-product + dietary-supplement safety + ingredient compliance testing.
• Counterfeit-medicine forensics — MoHAP Central Laboratories provides forensic analytical support for MoHAP + UAE Federal Customs Authority + Ministry of Interior + Dubai Police + Abu Dhabi Police investigations + WHO Global Surveillance & Monitoring System contributions.
• Capacity-building — MoHAP Central Laboratories hosts GHC + Arab League + WHO capacity-building programmes + training for GCC + Arab-region pharmaceutical analysts.
• GMP Inspectorate support — MoHAP Central Laboratories provides scientific + technical support for MoHAP + GCC harmonised GMP inspections of UAE + foreign manufacturing facilities.
• ESMA coordination — MoHAP Central Laboratories coordinates with the Emirates Authority for Standardization and Metrology (ESMA) on pharmaceutical + medical-device standards + accreditation.

MoHAP medical-device + IVD regulation operates under Federal Law 8 of 2019 + MoHAP Medical Devices framework with Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF + GCC-MD. Foreign manufacturers must appoint a UAE Authorised Representative.

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR + GHTF/IMDRF + GCC-MD; IVDs classified under separate UAE IVD framework.
• UAE Authorised Representative — UAE-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + MoHAP regulatory interface.
• ISO 13485:2016 — recognised by MoHAP + DHA + DoH Abu Dhabi as QMS evidence framework; UAE-specific overlay required including UAE quality records + Authorised Representative QMS interface.
• Reliance pathways — MoHAP accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence under reliance framework; CE Mark + FDA particularly central.
• GCC Medical Devices Harmonisation — MoHAP participates in GCC harmonised medical-device framework providing reliance + harmonised technical-file requirements across GCC Member States.
• Arab League Medical Devices Harmonisation — MoHAP participates in Council of Arab Ministers of Health medical-device harmonisation alongside Saudi SFDA + Egypt EDA + Jordan JFDA + Morocco DMP + Tunisia DPM/ANPM.
• Post-market vigilance — MoHAP operates medical-device adverse-event reporting through the UAE Federal Matériovigilance System coordinated by UAE Federal Pharmacovigilance Centre; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• IVD Réactovigilance — MoHAP operates dedicated IVD réactovigilance reflecting UAE's substantial clinical-laboratory infrastructure including DHA + DoH Abu Dhabi + Cleveland Clinic Abu Dhabi + Sheikh Khalifa Medical City + Mediclinic + NMC Healthcare.
• Cosmetic Notification — cosmetics require MoHAP + ESMA Cosmetic Notification + Arabic + English labelling; INCI-aligned ingredient listing + safety substantiation + cosmétovigilance reporting; substantively EU-aligned framework.
• Dietary Supplement Registration — MoHAP Dietary Supplements framework + ESMA coordination; substantively aligned with EU food-supplement framework + Codex Alimentarius.
• UAE UDI — MoHAP is progressively implementing UDI requirements substantively aligned with FDA UDI + EU EUDAMED UDI; UAE-specific overlay applies.
• Importation Permit — MoHAP Importation Permit required in addition to product registration for foreign-manufactured devices + drugs entering UAE; coordination with UAE Federal Customs Authority + Dubai Customs + Abu Dhabi Customs.
• Advanced Therapy Medicinal Products (ATMP) — DoH Abu Dhabi-coordinated framework for advanced therapy products + Abu Dhabi Stem Cell Center oversight + cell-therapy + gene-therapy + tissue-engineered product regulation.

MoHAP operates the UAE Federal Pharmacovigilance Programme through the UAE Federal Pharmacovigilance Centre (Dubai). UAE is a WHO Programme for International Drug Monitoring (PIDM) member + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The UAE Federal Pharmacovigilance Centre operates UAE's integrated pharmacovigilance + matériovigilance + cosmétovigilance centre — an integrated model providing efficient resource use across vigilance functions, with Emirate-level pharmacovigilance coordination through DHA + DoH Abu Dhabi.

• UAE Federal Pharmacovigilance Centre (Dubai) — integrated pharmacovigilance + matériovigilance + cosmétovigilance centre operating under MoHAP Pharmacovigilance Department coordination.
• DHA Pharmacovigilance Coordination — Dubai-Emirate-level pharmacovigilance coordination through DHA Health Regulation Department + Dubai Healthcare City Authority.
• DoH Abu Dhabi Pharmacovigilance Coordination — Abu Dhabi-Emirate-level pharmacovigilance coordination through DoH Abu Dhabi Health Regulation Sector + Abu Dhabi Global Market healthcare regulatory coordination.
• WHO PIDM Member — UAE is a WHO PIDM member + contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• UAE Pharmacovigilance Network — coordinated federal pharmacovigilance network with effector centres in major UAE hospitals (Dubai Hospital, Rashid Hospital, Latifa Hospital, Sheikh Khalifa Medical City, Cleveland Clinic Abu Dhabi, Mafraq Hospital, Tawam Hospital, Mediclinic, NMC Healthcare, King's College Hospital Dubai) + Marketing Authorisation Holders.
• Online ADR Reporting — MoHAP operates online ADR reporting via the MoHAP portal + Emirate-level DHA + DoH Abu Dhabi portals; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — MoHAP accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); MoHAP-specific submission timeline.
• Risk Management Plans (RMP) — MoHAP requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — MoHAP/UAE Federal Pharmacovigilance Centre operates targeted active-surveillance programmes including for HIV antiretrovirals + tuberculosis + COVID-19 vaccines + biologicals + sentinel-site hospital surveillance.
• AEFI Surveillance — UAE vaccine adverse-event surveillance aligned with WHO methodology; central to UAE National Immunization Programme + COVID-19 vaccine safety monitoring (including Sinopharm + Pfizer-BioNTech + Sputnik V + Hayat-Vax — UAE-Sinopharm joint-venture COVID-19 vaccine).
• Matériovigilance + Réactovigilance + Cosmétovigilance — MoHAP + DHA + DoH Abu Dhabi operate parallel matériovigilance for medical devices + réactovigilance for IVDs + cosmétovigilance for cosmetics.
• GCC Pharmacovigilance Network — UAE participates in GCC harmonised pharmacovigilance network providing efficient cross-Member-State safety signal sharing + coordinated response.

• WHO Listed Authority Candidate — MoHAP is a WHO Listed Authority candidate; substantial WHO PQ CRP participation + WHO PIDM membership + GCC Drug Registration co-leadership support trajectory.
• WHO PQ CRP Participating Authority — MoHAP is an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority.
• WHO PQ-Lab Candidate — MoHAP Central Laboratories is pursuing WHO PQ-Lab designation.
• GHC Member State — UAE MoHAP is a Gulf Health Council (GHC) Member State authority + active GCC Drug Registration co-leader alongside Saudi SFDA + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH.
• Arab League Council of Arab Ministers of Health Co-leader — MoHAP is an active pharmaceutical-harmonisation co-leader alongside Egyptian EDA + Saudi SFDA + Jordanian JFDA + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Lebanese MoH + Kuwait MoH + Bahrain NHRA.
• EMA Working Arrangement — MoHAP holds an EMA Working Arrangement covering information exchange + reliance + clinical-trial harmonisation + scientific cooperation.
• FDA Bilateral — MoHAP holds substantial cooperation with FDA reflecting US-UAE pharmaceutical trade + scientific cooperation + substantial US-trained UAE pharmaceutical professionals.
• MHRA Bilateral — MoHAP holds substantial cooperation with MHRA reflecting historical UK-Gulf ties + ongoing UK-UAE health cooperation + substantial UK-trained UAE pharmaceutical professionals.
• Health Canada + TGA + Swissmedic + MFDS Bilateral — MoHAP holds bilateral cooperation reflecting Stringent Regulatory Authority reliance practice.
• PIC/S Pre-Accession Applicant — MoHAP is on PIC/S Pre-Accession pathway; GMP Guide substantively aligned with PIC/S GMP + EU GMP + ICH Q7.
• ICH Observer — MoHAP is an ICH Observer; ICH guidelines extensively implemented in UAE regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• IMDRF Affiliate — MoHAP is an IMDRF Affiliate + draws on IMDRF guidance for medical-device regulation.
• AMRH Arab-region Cooperation — MoHAP cooperates with AMRH (African Medicines Regulatory Harmonisation) via Arab League / North African overlap reflecting UAE pharmaceutical re-export to sub-Saharan Africa.
• ICDRA + EMRO participation — active International Conference of Drug Regulatory Authorities + WHO Eastern Mediterranean Regional Office (EMRO) participant.
• Free-zone regulatory cooperation — Jebel Ali Free Zone + Dubai Healthcare City + Abu Dhabi Global Market substantial pharmaceutical logistics + regulatory + manufacturing infrastructure regulatory cooperation supporting global pharmaceutical re-export hub function.

• UAE Authorised Representative not properly designated — application rejected at MoHAP intake or post-approval compliance failure; UAE Authorised Representative must be UAE-resident legal entity with appropriate licensure.
• Arabic + English labelling deficiencies — Arabic + English labelling required; many applicants provide insufficient Arabic-language patient leaflet or use Modern Standard Arabic without UAE/Gulf dialect considerations.
• MoHAP federal vs DHA + DoH Abu Dhabi Emirate-level coordination not understood — applicants frequently file federal Drug Registration without coordinating Emirate-level Drug List inclusion at DHA + DoH Abu Dhabi; both federal Registration AND Emirate-level Drug List inclusion required for full UAE market access.
• MoHAP GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing UAE-specific MoHAP + GCC GMP clarifications + UAE quality records.
• UAE climate-zone stability data missing — UAE is Climate Zone IVb (hot/humid coastal) + Climate Zone IVa (hot/dry interior); applicants frequently provide insufficient zonal-specific stability data particularly for UAE summer ambient conditions.
• Bioequivalence centres + biowaiver — MoHAP + GCC Biowaiver Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice; alternatively many submit insufficient BE evidence where studies are required.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated MoHAP CRP review (90-day target); under-utilised by many applicants.
• GCC Drug Registration reliance under-utilised — GCC harmonised registration procedure across GCC Member States provides substantial acceleration; under-utilised by many applicants.
• EMA Working Arrangement reliance under-utilised — MoHAP-EMA Working Arrangement provides substantial acceleration for EMA-approved products; under-utilised by many applicants.
• FDA / Health Canada / TGA / Swissmedic / MHRA / MFDS reliance under-utilised — MoHAP operates substantial reliance on Stringent Regulatory Authority decisions; under-utilised by many applicants.
• Arab League harmonisation not leveraged — Council of Arab Ministers of Health pharmaceutical-harmonisation reliance under-utilised for Arab-Reference-Authority-assessed products.
• Essential Medicines + Vital Medicines accelerated pathway not leveraged — accelerated Federal Registration under-utilised; 90-120 working day target.
• Free-zone regulatory coordination not leveraged — Jebel Ali Free Zone + Dubai Healthcare City + Abu Dhabi Global Market substantial pharmaceutical logistics + regulatory + manufacturing infrastructure under-utilised for re-export hub strategy.
• Advanced Therapy Medicinal Products (ATMP) misdirected — DoH Abu Dhabi-coordinated framework for advanced therapy products + Abu Dhabi Stem Cell Center oversight; foreign ATMP sponsors frequently file federally without DoH Abu Dhabi coordination.
• Re-export hub strategy considerations — UAE pharmaceutical re-export to GCC + MENA + sub-Saharan Africa + South Asia + Central Asia + global markets frequently overlooked by foreign manufacturers considering UAE as purely a domestic-market opportunity.
• Variations strategy not planned — variations procedure substantively similar to EU + GCC but with UAE-specific federal + Emirate-level coordination + timelines + fee structure + Arabic/English-language requirements.
• Federal Registration renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration + market withdrawal.
• Clinical trial Emirate-level ethics coordination steps — UAE clinical trials require MoHAP CTA + Emirate-level Research Ethics Committee approval (DHA / DoH Abu Dhabi / MoHAP for Northern Emirates); sponsors sometimes overlook multi-Emirate clinical-trial coordination.
• Pharmacovigilance + UAE Federal PV Centre gaps — MoHAP GVP requirements substantively similar to ICH E2 + EU GVP + GCC GVP but with UAE-specific federal + Emirate-level pharmacovigilance coordination + Arabic + English ICSR.

V5 Ultimate provides the operational infrastructure UAE + foreign-supplier sites need for Federal Law 4 of 1983 + Federal Law 8 of 2019 + MoHAP + GCC + DHA + DoH Abu Dhabi GMP + Medical Devices framework + WHO PQ CRP + EMA Working Arrangement + GHC + Arab League + UAE Federal Pharmacovigilance Programme readiness.

• MoHAP + GCC GMP control framework — PIC/S + EU GMP + ICH Q7 + GCC GMP-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + UAE-specific clarifications + Climate Zone IVa/IVb stability monitoring.
• MoHAP Federal Registration dossier packaging — UAE CTD-aligned dossier structure with UAE Module 1 specifics + Module 3 stability + Arabic + English patient leaflet + Authorised Representative declarations + Federal Law 8 of 2019 framework.
• DHA + DoH Abu Dhabi Emirate-level coordination — Drug List inclusion + Emirate-level pharmacy + healthcare-facility + pharmaceutical-establishment licensing + Dubai Healthcare City + Abu Dhabi Global Market free-zone coordination.
• WHO PQ CRP workflow — MoHAP-as-CRP-participating-authority packaging with reduced dossier + accelerated MoHAP review (90-day target).
• GCC Drug Registration workflow — GCC harmonised registration procedure packaging supporting cross-Member-State market access across Saudi Arabia + UAE + Kuwait + Bahrain + Oman + Qatar.
• EMA Working Arrangement reliance workflow — MoHAP-EMA Working Arrangement packaging for EMA-approved products.
• FDA / Health Canada / TGA / Swissmedic / MHRA / MFDS reliance workflow — Stringent Regulatory Authority reliance packaging.
• Arab League workflow — Council of Arab Ministers of Health pharmaceutical-harmonisation packaging with Egyptian EDA + Saudi SFDA + Jordan JFDA + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Kuwait MoH + Bahrain NHRA coordination.
• Re-export hub workflow — UAE-as-pharmaceutical-re-export-hub packaging for substantial UAE pharmaceutical re-export to GCC + MENA + sub-Saharan Africa + South Asia + Central Asia + global markets supporting Jebel Ali Free Zone + Dubai Healthcare City + Abu Dhabi Global Market substantial pharmaceutical logistics + regulatory + manufacturing infrastructure.
• Essential Medicines + Vital Medicines accelerated workflow — UAE National Essential Medicines List + public-health emergency product packaging with 90-120 working day accelerated review.
• UAE Authorised Representative workflow — foreign-manufacturer Authorised Representative designation + role-management + UAE-specific post-market surveillance + MoHAP + DHA + DoH Abu Dhabi interface.
• UAE clinical-trial workflow — MoHAP CTA + Emirate-level Research Ethics Committee coordination (DHA / DoH Abu Dhabi / MoHAP for Northern Emirates) + multi-Emirate clinical-trial coordination + UAE SUSAR reporting via UAE Federal Pharmacovigilance Centre.
• MoHAP/UAE Federal PV Centre Pharmacovigilance integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Arabic + English ICSR + UAE Pharmacovigilance Network coordination + MoHAP + DHA + DoH Abu Dhabi portal submission + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting.
• Matériovigilance + Réactovigilance + Cosmétovigilance workflow — parallel matériovigilance + IVD réactovigilance + cosmétovigilance packaging coordinated through UAE Federal PV Centre + DHA + DoH Abu Dhabi.
• Medical-device + IVD + cosmetic + dietary-supplement workflow — Federal Law 8 of 2019 + MoHAP framework + ESMA standards dossier packaging + Class I-III classification + ISO 13485 + Authorised Representative + post-market vigilance + Advanced Therapy Medicinal Products via DoH Abu Dhabi.
• GCC + Arab League + EMA + AMRH regional bridging — for companies operating across GCC + MENA + sub-Saharan Africa + South Asia, V5 surfaces MoHAP + DHA + DoH Abu Dhabi + Saudi SFDA + Jordan JFDA + Egyptian EDA + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH harmonised dossier-element reuse alongside national-specific extensions.